RUBICON RESEARCH LIMITED (NSE: RUBICON, BSE: 544578) is a Mumbai, Maharashtra-based company in the Pharmaceuticals industry. With a market capitalisation of ₹28,526 Cr, it ranks #295 by market cap among the 6,197 Indian listed companies on FinBizNet, and #5 of 63 in Pharmaceuticals. At ₹1,675.00 (as of 16 Nov 2026), the share price is 11.8% below its 52-week high of ₹1,899.00 and 172.3% above its 52-week low of ₹615.20. The share price is up 162.7% over one year and up 3.5% over three months.
| Current Price | ₹1,675.00 |
|---|---|
| Market Cap | ₹28,526 Cr |
| NSE Symbol | RUBICON |
| BSE Code | 544578 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Pharmaceuticals |
| P/E Ratio | 112.3 |
| Return on Equity | 19.14% |
| Return on Assets | 11.74% |
| 52-Week Range | ₹615.20 – ₹1,899.00 |
| 1-Year Price Change | +162.7% |
| 3-Month Price Change | +3.5% |
| Beta (1Y) | 0.11 |
| Dividend Yield | 0.09% |
| Headquarters | Mumbai, Maharashtra |
| Website | www.rubicon.co.in |
| Revenue | ₹576 Cr |
|---|---|
| Net Profit | ₹90 Cr |
| Net Margin | 15.7% |
| EPS (Basic) | ₹5.47 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
RUBICON RESEARCH LIMITED reported revenue of ₹576 Cr in Q2 FY27, up 39.9% from ₹412 Cr in Q2 FY26 and up 7.9% from ₹534 Cr in Q1 FY27. It posted a net profit of ₹90 Cr for the quarter, against a net profit of ₹54 Cr in Q2 FY26 (up 67.9%). Across the 5 quarters from Q2 FY26 to Q2 FY27, quarterly revenue ranged from ₹412 Cr (Q2 FY26) to ₹576 Cr (Q2 FY27). The company was profitable in each of these 5 quarters.
| Quarter | Revenue | Net Profit | Net Margin |
|---|---|---|---|
| Q2 FY27 | ₹576 Cr | ₹90 Cr | 15.7% |
| Q1 FY27 | ₹534 Cr | ₹85 Cr | 15.9% |
| Q4 FY26 | ₹514 Cr | ₹77 Cr | 14.9% |
| Q3 FY26 | ₹476 Cr | ₹73 Cr | 15.3% |
| Q2 FY26 | ₹412 Cr | ₹54 Cr | 13.1% |
Consolidated figures (₹ crore, XBRL filings).
Promoters held 51.25% of RUBICON RESEARCH LIMITED's shares as of Sept 2026, against 59.99% in Oct 2025 (−8.74 percentage points). Delivery averaged 50.7% of traded volume across 16 NSE sessions (22 Oct 2026 – 13 Nov 2026).
Rubicon Research Limited operates as a specialty pharmaceutical company in India, the United States, and internationally. Its primary proprietary technologies for drug delivery comprising RubiSRL for the formulation of sustained release liquids using a combination of ion exchange and membrane diffusion controlled-release technologies; and RubiReten, a gastro-retentive system for drugs with poor solubility and a limited window of absorption. The company develops products in the areas of analgesics/pain management, hypokalemia, gastrointestinal, cardiovascular, skeletal muscle relaxants, metabolic, central nervous system, nicotine replacement therapy, and immunosuppressant. The company was incorporated in 1999 and is based in Mumbai, India.
1. Pharmaceutical Products (Generics, Speciality, API, Related Services, Etc.)-This segment engages in the research, development, and production of pharmaceutical products. 2. NA-NA 3. NA-NA 4. NA-NA
1. Pharmaceutical Products (Generics, Speciality, API, Related Services, Etc.)-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Abbott India Ltd. | ₹56,531 Cr | 36.3 | 34.46% | ₹1,814 Cr | -8.1% |
| Emcure Pharmaceuticals Ltd | ₹42,344 Cr | 47.9 | 19.57% | ₹2,820 Cr | +73.3% |
| Ajanta Pharma Limited | ₹41,474 Cr | 39.4 | 25.39% | ₹1,794 Cr | +27.8% |
| Piramal Pharma Ltd | ₹32,600 Cr | n/m | -4.00% | ₹2,617 Cr | +22.8% |
| RUBICON RESEARCH LIMITED | ₹28,526 Cr | 112.3 | 19.14% | ₹576 Cr | +162.7% |
| Caplin Point Laboratories Ltdte | ₹18,155 Cr | 28.3 | 19.94% | ₹630 Cr | +23.6% |
| Pfizer Ltd. | ₹17,811 Cr | 24.5 | 17.16% | ₹727 Cr | -24.2% |
| Eris Lifesciences Ltd | ₹17,691 Cr | 28.3 | 18.07% | ₹892 Cr | -17.5% |
| Astrazeneca Pharma India Ltd. | ₹16,078 Cr | 85.9 | 22.82% | ₹729 Cr | -34.3% |
Listed by market capitalisation. Ratios are shown for context only.
RUBICON RESEARCH LIMITED is trading at ₹1,675.00, with a market capitalisation of ₹28,526 Cr.
RUBICON RESEARCH LIMITED operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Pharmaceuticals).
RUBICON RESEARCH LIMITED has a P/E of 112.3 and a return on equity of 19.14%.
RUBICON RESEARCH LIMITED is listed on the NSE under the symbol RUBICON and on the BSE under the scrip code 544578.
RUBICON RESEARCH LIMITED's share price is up 162.7% over one year and up 3.5% over three months. Its 52-week range is ₹615.20 to ₹1,899.00.
In Q2 FY27, RUBICON RESEARCH LIMITED reported revenue of ₹576 Cr and net profit of ₹90 Cr, with basic EPS of ₹5.47 (consolidated, parsed from the company's exchange filing).
RUBICON RESEARCH LIMITED reported revenue of ₹576 Cr in Q2 FY27, up 39.9% from ₹412 Cr in Q2 FY26 and up 7.9% from ₹534 Cr in Q1 FY27.
Promoters held 51.25% of RUBICON RESEARCH LIMITED's shares as of Sept 2026, against 59.99% in Oct 2025 (−8.74 percentage points).
Data as of 16 Nov 2026. Descriptive market data only — not investment advice.